A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting RhGH, in Pediatric Growth Hormone Deficiency

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2015 Dec 18

PMID 26672637

Citations 18

Authors

Wayne V Moore

Huong Jil Nguyen

Gad B Kletter

Bradley S Miller

Douglas Rogers

David Ng

Jerome A Moore

Eric Humphriss

Jeffrey L Cleland

George M Bright

Affiliations

Soon will be listed here.

Abstract

Context: Somavaratan (VRS-317) is a long-acting form of recombinant human GH under development for children and adults with GH deficiency (GHD).

Objectives: To determine the optimal somavaratan dose regimen to normalize IGF-1 in pediatric GHD and to evaluate safety and efficacy of somavaratan over 6 months.

Design: Open-label, multicenter, single ascending dose study followed by 6-month randomized comparison of 3 dosing regimens.

Setting: Twenty-five United States pediatric endocrinology centers.

Patients: Naive-to-treatment, prepubertal children with GHD (n = 68).

Intervention(s): Patients received single sc doses of somavaratan (0.8, 1.2, 1.8, 2.7, 4.0, or 6.0 mg/kg) during the 30-day dose-finding phase, then were randomized to somavaratan 1.15 mg/kg weekly, 2.5 mg/kg twice monthly, or 5.0 mg/kg monthly for 6 months.

Main Outcome Measures: Safety, pharmacokinetics, pharmacodynamics, 6-month height velocity (HV).

Results: Somavaratan pharmacokinetics was linearly proportional to dose; dose-dependent increases in the magnitude and duration of IGF-1 responses enabled weekly, twice-monthly or monthly dosing. A single dose of somavaratan sustained IGF-1 responses for up to 1 month. No somavaratan or IGF-1 accumulation occurred with repeat dosing. Mean annualized HVs for somavaratan administered monthly, twice monthly, or weekly (7.86 ± 2.5, 8.61 ± 2.7, and 7.58 ± 2.5 cm/y, respectively) were similar between groups. Adverse events were mostly mild and transient.

Conclusions: Somavaratan demonstrated clinically meaningful improvements in HV and IGF-1 in prepubertal children with GHD, with no significant differences between monthly, twice-monthly, or weekly dosing.

Citing Articles

Expression, Purification, and Biological Evaluation of XTEN-GCSF in a Neutropenic Rat Model.

Nikravesh F, Gholami P, Bayat E, Talebkhan Y, Mirabzadeh E, Damough S Appl Biochem Biotechnol. 2023; 196(2):804-820.

PMID: 37209276 DOI: 10.1007/s12010-023-04522-w.

Long-term Pegylated GH for Children With GH Deficiency: A Large, Prospective, Real-world Study.

Hou L, Huang K, Gong C, Luo F, Wei H, Liang L J Clin Endocrinol Metab. 2023; 108(8):2078-2086.

PMID: 36669772 PMC: 10348466. DOI: 10.1210/clinem/dgad039.

Interventions Designed to Improve Adherence to Growth Hormone Treatment for Pediatric Patients and Their Families: A Narrative Review.

Graham S, Quirke-McFarlane S, Auyeung V, Weinman J Pharmaceutics. 2022; 14(11).

PMID: 36365191 PMC: 9695555. DOI: 10.3390/pharmaceutics14112373.

PEGylated Recombinant Human Growth Hormone Jintrolong Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency Patients.

Wu W, Zhou J, Wu C, Zhou Q, Li X, Zhang Y Front Endocrinol (Lausanne). 2022; 13:821588.

PMID: 35909512 PMC: 9336684. DOI: 10.3389/fendo.2022.821588.

Development of a Predictive Enrichment Marker for the Oral GH Secretagogue LUM-201 in Pediatric Growth Hormone Deficiency.

Bright G, Do M, McKew J, Blum W, Thorner M J Endocr Soc. 2021; 5(6):bvab030.

PMID: 33982679 PMC: 8101275. DOI: 10.1210/jendso/bvab030.

References

Kelly A, Winer K, Kalkwarf H, Oberfield S, Lappe J, Gilsanz V . Age-based reference ranges for annual height velocity in US children. J Clin Endocrinol Metab. 2014; 99(6):2104-12. PMC: 4037731. DOI: 10.1210/jc.2013-4455. View

Yuen K, Conway G, Popovic V, Merriam G, Bailey T, Hamrahian A . A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults. J Clin Endocrinol Metab. 2013; 98(6):2595-603. PMC: 3667252. DOI: 10.1210/jc.2013-1437. View

Ranke M, Lindberg A, Cowell C, Albertsson Wikland K, Reiter E, Wilton P . Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database). J Clin Endocrinol Metab. 2003; 88(1):125-31. DOI: 10.1210/jc.2002-020867. View

Mire-Sluis A, Barrett Y, Devanarayan V, Koren E, Liu H, Maia M . Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004; 289(1-2):1-16. DOI: 10.1016/j.jim.2004.06.002. View

Tanner J, Davies P . Clinical longitudinal standards for height and height velocity for North American children. J Pediatr. 1985; 107(3):317-29. DOI: 10.1016/s0022-3476(85)80501-1. View

Smith S, Hindmarsh P, Brook C . Compliance with growth hormone treatment--are they getting it?. Arch Dis Child. 1993; 68(1):91-3. PMC: 1029189. DOI: 10.1136/adc.68.1.91. View

Blethen S, Compton P, Lippe B, Rosenfeld R, August G, Johanson A . Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency. J Clin Endocrinol Metab. 1993; 76(3):574-9. DOI: 10.1210/jcem.76.3.8445013. View

Ranke M, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K . Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth.... J Clin Endocrinol Metab. 1999; 84(4):1174-83. DOI: 10.1210/jcem.84.4.5634. View

Vance M, Mauras N . Growth hormone therapy in adults and children. N Engl J Med. 1999; 341(16):1206-16. DOI: 10.1056/NEJM199910143411607. View

10.

Ranke M, Lindberg A, Albertsson-Wikland K, Wilton P, Price D, Reiter E . Increased response, but lower responsiveness, to growth hormone (GH) in very young children (aged 0-3 years) with idiopathic GH Deficiency: analysis of data from KIGS. J Clin Endocrinol Metab. 2005; 90(4):1966-71. DOI: 10.1210/jc.2004-1051. View

11.

DesRosiers P, OBrien F, Blethen S . Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth. Pediatr Endocrinol Rev. 2006; 2 Suppl 3:327-31. View

12.

Chihara K, Kato Y, Kohno H, Takano K, Tanaka T, Teramoto A . Efficacy and safety of growth hormone (GH) in the treatment of adult Japanese patients with GH deficiency: a randomised, placebo-controlled study. Growth Horm IGF Res. 2006; 16(2):132-42. DOI: 10.1016/j.ghir.2006.03.012. View

13.

Ranke M, Lindberg A, Price D, Darendeliler F, Albertsson-Wikland K, Wilton P . Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Horm Res. 2007; 68(2):53-62. DOI: 10.1159/000098707. View

14.

Kapoor R, Burke S, Sparrow S, Hughes I, Dunger D, Ong K . Monitoring of concordance in growth hormone therapy. Arch Dis Child. 2007; 93(2):147-8. DOI: 10.1136/adc.2006.114249. View

15.

Rosenfeld R, Bakker B . Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract. 2008; 14(2):143-54. DOI: 10.4158/EP.14.2.143. View

16.

de Lind van Wijngaarden R, Siemensma E, Festen D, Otten B, van Mil E, Rotteveel J . Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2009; 94(11):4205-15. DOI: 10.1210/jc.2009-0454. View

17.

Schellenberger V, Wang C, Geething N, Spink B, Campbell A, To W . A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol. 2009; 27(12):1186-90. DOI: 10.1038/nbt.1588. View

18.

Ranke M, Lindberg A . Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab. 2010; 95(3):1229-37. DOI: 10.1210/jc.2009-1471. View

19.

Midyett L, Rogol A, Van Meter Q, Frane J, Bright G . Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2009; 95(2):611-9. DOI: 10.1210/jc.2009-0570. View

20.

Noble S, Leyland K, Findlay C, Clark C, Redfern J, Mackenzie J . School based screening for hypothyroidism in Down's syndrome by dried blood spot TSH measurement. Arch Dis Child. 2000; 82(1):27-31. PMC: 1718179. DOI: 10.1136/adc.82.1.27. View